In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards. 25 November 2024
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Belgian biotech firm Ablynx today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018. 24 January 2018
In the first of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, senior executives from Boehringer Ingelheim, Teva Pharmaceutical Industries and Pfizer ask how pharma waving goodbye to brand-led strategies is changing relationships with HCPs. 24 January 2018
Merck & Co UK unit MSD has today announced the appointment of Dr Fiona Marshall to lead its new discovery research facility in London, focused on early bioscience discovery and entrepreneurial innovation. 22 January 2018
For years, China has been viewed with a mixture of excitement, optimism and suspicion by western pharmaceutical firms, with nervous investors wary of the relatively opaque political and economic environment in the country. 22 January 2018
Japanese GPCR medicines specialist Sosei Group today announced that Dr Fiona Marshall has resigned from her position as executive vice president and chief scientific officer of Sosei to assume a senior role outside the company. 19 January 2018
The cost of prescription drugs is at the forefront of discussions among patients, advocacy groups, prescribers, payers, pharmaceutical companies, and policy makers. One factor – though not the only factor – in driving the cost of prescription drugs is the availability of competing products. 19 January 2018
Jordan-headquartered Hikma Pharmaceuticals today announced that Surendera Tyagi will join the company as group chief scientific officer and global head of R&D. 15 January 2018
The Russian government has announced that it will provide subsidies for domestic drugmakers and foreign companies operating in the local market for the partial cover their costs, associated with the forthcoming introduction of labeling procedure in the domestic pharmaceutical market, reports The Pharma Letter’s local correspondent. 13 January 2018
With sales of 97 billion yen ($970 million) for the first half of 2017, a rise of nearly 50% on the previous year, the gastroenterology product Entyvio (vedolizumab) is the best-selling brand of Japanese pharma major Takeda Pharmaceutical. 11 January 2018
Novartis today revealed that Elizabeth (Liz) Barrett, currently global president oncology at Pfizer, will join the company as chief executive of Novartis Oncology and a member of the executive committee of Novartis, effective February 1, 2018 11 January 2018
This year marks the 350th anniversary of German science and technology group Merck KGaA, a milestone that will remind the industry and wider world that it is the oldest operating pharma company in existence anywhere. 10 January 2018
According to US Food and Drug Administration regulations, the regulatory agency may refuse to file a new drug application (NDA) or biologics license application (BLA) when either is deemed incomplete, writes Dr Nicola Davies in her monthly blog for The Pharma Letter. 10 January 2018
French drugmaker Ipsen today announced the promotion of Dr Aidan Murphy as executive vice president, technical operations, effective January 1, 2018. 10 January 2018
Andrew Rut, chief executive of MyMeds&Me, a provider of adverse event and product quality capture software, considers in an Expert View piece how pharma’s ability to run efficient clinical trials is in danger of being compromised by GDPR and a hardening of attitudes on data privacy globally. 9 January 2018
Dr Peter Fellner, who has served as chairman of Belgian biotech firm Ablynx since 2013, has decided to resign from the board with immediate effect. 9 January 2018
US biotech Neurocrine Biosciences has named an experienced Eli Lilly executive its new chief medical officer after Christopher O'Brien announced that he would be retiring. 8 January 2018
Ophthalmic drug specialist Aerie Pharmaceuticals has appointed Julia Williams as director of medical affairs, initially focused on the launch of Rhopressa (netarsudil ophthalmic solution) 0.02%. 3 January 2018